Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SPT-2101
- Development stage
- Phase 1
- Lead developer
- Spiral Therapeutics
- Modality
- Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Administration
- Intratympanic
01
Overview
SPT-2101 is a long-acting, sustained-release formulation of dexamethasone developed by Spiral Therapeutics for the treatment of Meniere's disease. It utilizes Spiral’s proprietary Minimally Invasive Cochlear System (MICS™) to deliver a 6% dexamethasone gel directly to the round window membrane of the inner ear, enabling targeted and extended drug release. This approach aims to provide precise, durable therapy for inner ear disorders while minimizing invasiveness. Clinical trials have demonstrated significant reductions in vertigo frequency and severity among patients with Meniere's disease, with no serious adverse events reported[1][3][4][7]. The mechanism of action is through glucocorticoid receptor agonism, providing anti-inflammatory and immunosuppressive effects[10].
- Other names
- SPT-2101SPT2101SPT 2101
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on SPT-2101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPT-2101.